The Centre for Mental Health Research and Innovation is a trial site for cutting edge research studies for serious mental health disorders, including a trial for treatment-resistant depression. It is accelerating research into emerging psychedelic therapies, supporting therapist training, evaluating real-world evidence, and enabling research into digital technologies that may enable personalised, predictive and preventative care models.
The Centre is part of a pioneering long-term strategic partnership between biotechnology company Compass Pathways, South London and Maudsley NHS Foundation Trust, and the Psychoactive Trials Group at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
It is located at Maudsley Hospital, one of the sites of South London and Maudsley. It is a dedicated and purpose-built space for late-stage clinical trials, and is directed by leading clinical investigator Dr James Rucker.
Psychoactive Trials Group
The psychoactive trials group based at the IoPPN brings together researchers and clinicians to study psychedelics as a treatment for a range of mental health conditions including treatment-resistant depression, anorexia and post-traumatic stress disorder. This research has also taken place at the NIHR King’s CRF and been supported by our NIHR Maudsley BRC, whose director Professor Grainne McAlonan is leading an investigative study into psilocybin and autism.
Professor Matthew Hotopf CBE Executive Dean at IoPPNThis partnership shows how working across academia, the NHS and industry can accelerate the development of exciting new treatments for mental disorders. Early stage support from funders such as the NIHR make it possible to establish the potential of novel treatments so we can work between partners in different sectors to find better treatments, which are so badly needed. The new Centre will help accelerate the development of new much-needed therapies.
